| Market Capitalization (Millions $) |
236 |
| Shares
Outstanding (Millions) |
215 |
| Employees |
229 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-252 |
| Cash Flow (TTM) (Millions $) |
-9 |
| Capital Exp. (TTM) (Millions $) |
1 |
Allogene Therapeutics Inc
Allogene Therapeutics Inc is a clinical-stage biotechnology company based in South San Francisco, California. Founded in 2017, the company focuses on the development of innovative allogeneic CAR T-cell therapies for treating cancer. Allogeneic CAR T-cell therapy is a type of immunotherapy that uses genetically modified T-cells from healthy donors to target and destroy cancer cells in patients.
The goal of Allogene is to provide accessible and effective cell therapies to patients by utilizing off-the-shelf CAR T-cell products instead of relying on patient-specific cell engineering, which can be costly and time-consuming. The company has developed a proprietary technology platform known as AlloCAR to create universal CAR T-cells that can be administered to a wide range of patients without the need for individualized manufacturing.
Allogene has a pipeline of product candidates targeting different types of blood cancers, including acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma. The company has also forged collaborations with pharmaceutical companies and academic institutions to further advance its research and development efforts.
As of 2021, Allogene is conducting several clinical trials to evaluate the safety and efficacy of its CAR T-cell therapies. If successful, Allogene's therapies could significantly impact the field of cancer treatment by providing a more accessible and efficient approach to immunotherapy.
Company Address: 210 East Grand Avenue South San Francisco 94080 CA
Company Phone Number: 457-2700 Stock Exchange / Ticker: NASDAQ ALLO
|
2% 